In vivo [125I]-iodobenzovesamicol binding reflects cortical cholinergic deficiency induced by specific immunolesion of rat basal forebrain cholinergic system

Nuclear Medicine and Biology

Volumn 27, Issue 1, 2000, Pages 23-31

  Sorger, Dietlind ^a   Schliebs, Reinhard ^a   Kämpfer, Ingrid ^a   Rossner, Steffen ^a   Heinicke, Jochen ^a   Dannenberg, Claudia ^a   Georgi, Peter ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Acetylcholinesterase; Cholinergic immunolesion; Iodobenzovesamicol; Vesamicol receptor

Indexed keywords

ACETYLCHOLINESTERASE; IMMUNOTOXIN; IODINE 125; SAPORIN; VESAMICOL; VESAMICOL DERIVATIVE; VESICULAR ACETYLCHOLINE TRANSPORTER; 5 IODOBENZOVESAMICOL; 5-IODOBENZOVESAMICOL; CHOLINERGIC RECEPTOR; DIAGNOSTIC AGENT; PIPERIDINE DERIVATIVE; RADIOACTIVE IODINE; SIGMA OPIATE RECEPTOR; TETRALIN DERIVATIVE; VESAMICOL RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN INJURY; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; FEMALE; FOREBRAIN; HISTOCHEMISTRY; IMMUNOTOXICITY; IN VIVO STUDY; NONHUMAN; RAT; ANALYSIS OF VARIANCE; ANIMAL; CHOLINERGIC NERVE; METABOLISM; PATHOLOGY; RADIOGRAPHY; TISSUE DISTRIBUTION; WISTAR RAT;

ACETYLCHOLINESTERASE; ANALYSIS OF VARIANCE; ANIMALS; AUTORADIOGRAPHY; CHOLINERGIC FIBERS; FEMALE; IODINE RADIOISOTOPES; PIPERIDINES; PROSENCEPHALON; RATS; RATS, WISTAR; RECEPTORS, CHOLINERGIC; RECEPTORS, SIGMA; TETRAHYDRONAPHTHALENES; TISSUE DISTRIBUTION;

EID: 0033625014     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(99)00087-6     Document Type: Article

References (52)

1. 3H]Vesamicol binding in brain Autoradiographic distribution, pharmacology, and effects of cholinergic lesions . Synapse. 2:1988;486-493.
2. Andrä J., Lojda Z. A histochemical method for the demonstration of acetylcholinesterase activity using semipermeable membranes. Histochemistry. 84:1986;575-579.
3. Bahr B.A., Parsons S.M. Demonstration of a receptor in Torpedo synaptic vesicles for the acetylcholine storage blocker 1-trans-2-(4-phenylpiperidino)cyclohexanol. Proc. Natl. Acad. Sci. USA. 83:1986;2267-2270.
4. Bahr B.A., Clarkson E.D., Rogers G.A., Noremberg K., Parsons S.M. A kinetic and allosteric model for the acetylcholine transporter-vesamicol receptor in synaptic vesicles. Biochemistry. 31:1992;5752-5762.
5. Bigl V., Schliebs R. Simulation of cholinergic deficits-a novel experimental approach to study pathogenetic aspects of Alzheimer's disease. J. Neural Transm. 53:1998;237-247.
6. Claus J.J., Dubois E.A., Booij J., Habraken J., De Munck J.C., Van Herk M., Verbeeten B. Jr, Van Royen E.A. Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography. Eur. J. Nucl. Med. 24:1997;602-608.
7. Efange S.M.N., Dutta A.K., Michelson R.H., Kung H.F., Thomas J.R., Billings J., Boudreau R.J. Radioiodinated 2-hydroxy-3-(4-iodophenyl)-1-(4-phenylpiperidinyl) propane Potential radiotracer for mapping central cholinergic innervation in vivo . Nucl. Med. Biol. 19:1992;337-348.
8. 125I]MIBT) Potential radioligand for mapping central cholinergic innervation . J. Med. Chem. 36:1993;1754-1760.
9. Efange S.M.N., Khare A.B., Foulon C., Akella S.K., Parsons S.M. Spirovesamicols Conformationally restricted analogs of 2-(4-phenylpiperidino) cyclohexanol (vesamicol, AH 5183) as potential modulators of presynaptic cholinergic function . J. Med. Chem. 37:1994;2574-2582.
10. Efange S.M.N., Mach R.H., Smith C.R., Khare A.B., Foulon C., Akella S.K., Childers S.R., Parsons S.M. Vesamicol analogues as sigma ligands. Molecular determinants of selectivity at the vesamicol receptor. Biochem. Pharmacol. 49:1995;791-797.
11. Hardy J., Adolfsson R., Alafuzoff I., Bucht G., Marcusson J., Nyberg P., Perdahl E., Wester P., Winblad B. Transmitter deficits in Alzheimer's disease. Neurochem. Int. 7:1985;545-563.
12. Heckers S., Ohtake T., Wiley R.G., Lappi D.A., Geula C., Mesulam M.M. Complete and selective denervation of rat neocortex and hippocampus but not amygdala by an immunotoxin against the p75 NGF receptor. J. Neurosci. 14:1994;1271-1289.
13. 18F]Fluoro-A-85380, an in vivo tracer for the nicotinic acetylcholine receptors. Nucl. Med. Biol. 25:1998;599-603.
14. Irie T., Fukushi K., Akimoto Y., Tamagami H., Nozaki T. Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AChE) in vivo. Nucl. Med. Biol. 21:1994;801-808.
15. Iyo M., Namba H., Fukushi K., Shinotoh H., Nagatsuka S., Suhara T., Sudo Y., Suzuki K., Irie T. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet. 349:1997;1805-1809.
16. Jung Y.W., Van Dort M.E., Gildersleeve D.L., Wieland D.M. A radiotracer for mapping cholinergic neurons of the brain. J. Med. Chem. 33:1990;2065-2068.
17. Jung Y.W., Frey K.A., Mulholland G.K., Del Rosario R., Sherman P.S., Raffel D.M., Van Dort M.E., Kuhl D.E., Gildersleeve D.L., Wieland D.M. Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol. J. Med. Chem. 39:1996;3331-3342.
18. Kilbourn M.R., Jung Y.W., Haka M.S., Gildersleeve D.L., Kuhl D.E., Wieland D.M. Mouse brain distribution of a carbon-11 labeled vesamicol derivative Presynaptic marker of cholinergic neurons . Life Sci. 47:1990;1955-1963.
19. 11C]PMP). Synapse. 22:1996;123-131.
20. 3H]Vesamicol binding in human brain cholinergic deficiency disorders. Neurosci. Lett. 117:1990;347-352.
21. Kuhl D.E., Koeppe R.A., Fessler J.A., Minoshima S., Ackermann R.J., Carey J.E., Gildersleeve D.L., Frey K.A., Wieland D.M. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J. Nucl. Med. 35:1994;405-410.
22. Kuhl D.E., Minoshima S., Fessler J.A., Frey K.A., Foster N.L., Ficaro E.P., Wieland D.M., Koeppe R.A. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease and Parkinson's disease. Ann. Neurol. 40:1996;399-410.
23. Lundqvist H., Långström B., Nordberg A. Use of carbon-11 nicotine in PET studies. Eur. J. Nucl. Med. 24:1997;825-826.
24. Lysakowski A., Wainer B.H., Bruce G., Hersh L.B. An atlas of the regional and laminar distribution of choline acetyltransferase immunoreactivity in rat cerebral cortex. Neuroscience. 28:1989;291-336.
25. 18F](+)-4-fluorobenzyltrozamicol In vitro binding studies and positron emission tomography studies in nonhuman primates . Synapse. 25:1997;368-380.
26. Marien M.R., Parsons S.M., Altar C.A. Quantitative autoradiography of brain binding sites for the vesicular acetylcholine transport blocker 2-(4-phenylpiperidino)cyclohexanol (AH5183). Proc. Natl. Acad. Sci. USA. 84:1987;876-880.
27. Marshall I.G., Parsons S.M. The vesicular acetylcholine transport system. Trends Neurosci. 10:1987;174-177.
28. 11C]methylamino benzovesamicol. J. Labelled Compd. Radiopharm. XXXI:1992;253-259.
29. Mulholland G.K., Otto C.A., Jewett D.M., Kilbourn M.R., Koeppe R.A., Sherman P.S., Petry N.A., Carey J.E., Atkinson E.R., Archer S., Frey K.A., Kuhl D.E. Synthesis, rodent biodistribution, dosimetry, metabolism, and monkey images of carbon-11-labeled (+)-2□-tropanyl benzilate A central muscarinic receptor imaging agent . J. Nucl. Med. 33:1992;423-430.
30. 18F]fluorethoxy-benzovesamicol, a radiotracer for cholinergic neurons. J. Labelled Compd. Radiopharm. XXXIII:1993;583-591.
31. 18F]Fluoroethoxy-benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses. Synapse. 30:1998;263-274.
32. Namba H., Iyo M., Fukushi K., Shinotoh H., Nagatsuka S., Suhara T., Sudo M., Suzuki K., Irie T. Human cerebral acetylcholinesterase activity measured with positron emission tomography Procedure, normal values and effect of age . Eur. J. Nucl. Med. 26:1999;135-143.
33. Nguyen T.B., Snyder S.H., Kilbourn M.R. Synthesis of carbon-11 labeled piperidine esters as potential in vivo substrates for acetylcholinesterase. Nucl. Med. Biol. 25:1998;761-768.
34. Nordberg A., Hartvig P., Lilja A., Vitanen M., Amberla K., Lundquist H., Ulin J., Anderssohn Y., Langström B. and Winblad B. (1991) Brain nicotinic receptor deficits in Alzheimer patients as studied by positron emission tomography. In Alzheimer's Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies (Edited by Iqbal K., McLachlan D. R. C., Winblad B., and Wisniewski H. M.), pp. 517-523. John Wiley & Sons Ltd., New York, NY, USA.
35. Parsons S.M., Bahr B.A., Rogers G.A., Clarkson E.D., Noremberg K., Hicks B.W. Acetylcholine transporter-vesamicol receptor pharmacology and structure. Prog. Brain Res. 98:1993;175-181.
36. Perry E.K. The cholinergic hypothesis-ten years on. Br. Med. Bull. 42:1986;63-69.
37. Rogers G.A., Parsons S.M., Anderson D.C., Nilsson L.M., Bahr B.A., Kornreich W.D., Kaufman R., Jacobs R.S., Kirtman B. Synthesis, in vitro acetylcholine-storage-blocking activities, and biological properties of derivatives and analogues of trans-2-(4-phenylpiperidino)cyclohexanol (Vesamicol). J. Med. Chem. 32:1989;1217-1230.
38. Rogers G.A., Kornreich W.D., Hand K., Parsons S.M. Kinetic and equilibrium characterization of vesamicol receptor-ligand complexes with picomolar dissociation constants. Mol. Pharmacol. 44:1993;633-641.
39. 18F-labeled vesamicol derivatives Syntheses and preliminary in vivo small animal positron emission tomography evaluation . Nucl. Med. Biol. 21:1994;219-230.
40. Rossner S., Perez-Polo J.R., Wiley R.G., Schliebs R., Bigl V. Differential expression of immediate early genes in distinct forebrain cholinergic system. J. Neurosci. Res. 38:1994;282-293.
41. Rossner S., Schliebs R., Perez-Polo J.R., Wiley R.G., Bigl V. Differential changes in cholinergic markers from selected brain regions after specific immunolesion of the rat cholinergic basal forebrain system. J. Neurosci. Res. 40:1995;31-43.
42. 3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions. Neuroscience. 35:1990;327-333.
43. Sato A., Sato Y. Cholinergic neuronal regulation of regional cerebral blood flow. Alzheimer Dis. Assoc. Disord. 9:1995;28-38.
44. Schliebs R., Rossner S., Bigl V. Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system-a useful tool to produce cortical cholinergic dysfunction. Prog. Brain Res. 109:1996;253-264.
45. Shiba K., Mori H., Matsuda H., Tsuji S., Tonami N., Hisada K. In vivo characterization of radioiodinated 2-(4-phenylpiperidino)cyclohexanol (vesamicol) analogs Potential radioligand for mapping presynaptic cholinergic neurons . Nucl. Med. Biol. 22:1995;823-828.
46. Tavitian B., Pappata S., Planas A.M., Jobert A., Bonnot-Lours S., Crouzel C., DiGiamberardino L. In vivo visualization of acetylcholinesterase with positron emission tomography. Neuroreport. 4:1993;535-538.
47. 125I-labeled cholinergic nerve marker (-)-5-iodobenzovesamicol. Nucl. Med. Biol. 20:1993;929-937.
48. Weinberger D.R., Jones D., Reba R.C., Mann U., Coppola R., Gibson R., Gorey J., Braun A., Chase T.N. A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia. J. Neuropsych. Clin. Neurosci. 4:1992;239-248.
49. Wenk G.L., Mobley S.L. Choline acetyltransferase activity and vesamicol binding in Rett syndrome and in rats with nucleus basalis lesions. Neuroscience. 73:1996;79-84.
50. Widen L., Eriksson L., Ingvar M., Parsons S.M., Rogers G.A., Stone-Elander S. Positron emission tomographic studies of central cholinergic nerve terminals. Neurosci. Lett. 136:1992;1-4.
51. Wiley R.G., Oeltmann T.N., Lappi D.A. Immunolesioning Selective destruction of neurons using immunotoxin to rat NGF receptor . Brain Res. 562:1991;149-153.
52. Wyper D.J., Brown D., Patterson J., Owens J., Hunter R., Teasdale E., McCulloch J. Deficits in iodine-labelled 3-quinuclidinyl benzilate binding in relation to cerebral blood flow in patients with Alzheimer's disease. Eur. J. Nucl. Med. 20:1993;379-386.